Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
  • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
  • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
  • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
  • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
  • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
  • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
  • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
  • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
  • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
  • A61K9/7076—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising ingredients of undetermined constitution or reaction products thereof, e.g. rosin or other plant resins
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Definitions

• This invention concerns a patch applied to skins. More specifically, it relates to a patch giving less physical stimulations upon peeling such as pulling to hairs or skins and having good tack during use.
• patches or sticking plasters incorporating anti-inflammatory/analgesic agents such as methyl salicylate or L-menthol into a plaster layer have been developed and marketed as typical products.
• patches or sticking plaster agents are prepared by forming an adhesive on a support made of films, non-woven fabrics or woven fabrics and have been used with an aim of protecting skins after suture and for anti-inflammatory and analgesic purpose to inflammation of shoulders, elbows, knees and waists.
• Japanese Patent Laid-Open No. 225314/1988 discloses a topical patch or sticking plaster agent formed by blending a water absorptive polymer to absorb and adsorb sweats or secretions discharged from skins thereby mitigating steaming or skin eruptions.
• Japanese Patent Laid-Open No. 157423/1995 discloses a percutanous patch or sticking plaster agent with an aim of mitigating skin stimulations by setting the tack, thickness and moisture permeability of the patch or sticking plaster agent each within a specified range.
• This invention has been achieved for saving the problems in the patch or sticking plaster agent described above and intends to provide a patch with less stimulations to skins, excellent in long time store stability and heat stability, and having good tack during use.
• the present inventors have made earnest studies for attaining the foregoing purpose and have accomplished this invention based on the finding that physical stimulations upon peeling such as pulling hairs or skins can be moderated and damages to skins can be suppressed effectively and excellent long time stability is obtainable by blending two or more of poly isobutylenes of different average molecular weight to an adhesive containing a styrene-isoprene-styrene block copolymer, a tackifier, a plasticizer and a pharmaceutically effective ingredient in ingredients of a base agent and defining the viscosity of the adhesive of the patch to 1,500-30,000 poise (at 60° C.) and the tack of the patch to 5-200 g/10 mm.
• the patch according to this invention has the following constitution for attaining the purpose.
• this invention concerns a patch comprising a styrene-isoprene-styrene block copolymer, polyisobuytylene, a tackifier, a plasticizer and a pharmaceutical ingredient in which two or more of polyisobutylenes of different average molecular weight are used in combination, the viscosity of the adhesive of the patch is between 1,500 and 30,000 poise (at 60° C.) and the tack of the patch is from 5 to 200 g/10 mm.
• this invention has a feature in that the styrene-isoprene-styrene block copolymer has a weight average molecular weight of 100,000 to 300,000 with the blending amount thereof being from 10 to 40% by mass and that at least two kinds of the polyisobutylene having different viscosity average molecular weight are blended, one having a viscosity average molecular weight from 5,000 to 15,000 with the blending amount thereof being from 1 to 20% by mass and other having a viscosity average molecular weight of 5,000 to 20,000 with the blending amount thereof being from 0.2 to 15% by mass.
• this invention has a feature in blending a tackifier having a softening point of from 60° C. to 150° C. and the blending amount thereof from 5 to 50% by mass. Further, it has a feature in blending a plasticizer with a viscosity of from 10 to 100 centistokes (at 40° C.) and with a blending amount thereof from 10 to 70% by mass.
• this invention has a feature in blending a pharmaceutically effective ingredients with the blending amount thereof from 0.001 to 30% by mass.
• the styrene-isoprene-styrene block copolymer in this invention preferably has a weight average molecular weight of 100,000 to 300,000 and can include, for example, KRATON D-KX401CS or D-1107CU (manufactured by Shell Chemical Co. Ltd.), SIS-5000 or SIS-5002 (manufactured by Japan Synthetic Rubber Co. Ltd.), Quintack 3530, 3421 or 3570C (manufactured by Nippon Zeon Co. Ltd.) and Solprene 428 (manufactured by Phillip Petroleum Co. Ltd).
• KRATON D-KX401CS or D-1107CU manufactured by Shell Chemical Co. Ltd.
• SIS-5000 or SIS-5002 manufactured by Japan Synthetic Rubber Co. Ltd.
• Quintack 3530, 3421 or 3570C manufactured by Nippon Zeon Co. Ltd.
• Solprene 428 manufactured by Phillip Petroleum Co. Ltd.
• the blending amount is within a range from 10 to 50% by mass, preferably, from 13 to 40% by mass and, more preferably, from 15 to 30% by mass.
• Adhesion to skins, pains upon peeling and skin eruptions are greatly improved by using the styrene-isoprene-styrene block copolymer of this invention having the weight average molecular weight described above and at the blending ratio described above and, further preferably, by controlling the viscosity and the tack. If the blending amount is less than 10% by mass, it is not preferred since the cohesion or the shape retainability is reduced. Further, if the blending amount is 50% by mass or more, the cohesion of the base agent increases to undesirably lower the tack, make the plaster not uniform and deteriorate the operationability.
• One of the features of this invention resides in the use of two or more kinds of polyisobutylene of different average molecular weight in combination and a combination of a polyisobutylene having a viscosity average molecular weight (according to Staudinger method) of 5,000 to 150,000 and a polyisobutylene having a viscosity average molecular weight of 50,000 to 200,000 is preferred and it is further preferred to blend the polyisobutylenes described above each at the specified blending amount.
• Polyisobutylene having a viscosity average molecular weight from 5,000 to 150,000 can include, for example, Vistanex LM-MS, LM-MH (manufactured by Exxon Chemical Co. Ltd.), Tetrax 4T, 5T and 6T (manufactured by Nippon Petrochemical Co. Ltd.), Opanol B12SF and B15SF (manufactured by BASF Japan Co. Ltd.), and one or more of them can be blended.
• the blending amount is from 1 to 20% by mass, preferably, 2 to 18% by mass and, more preferably, 4 to 15% by mass. When the blending amount is less than 1% by mass, it is not preferred since the tack is insufficient. Further, if the blending amount is 20% by mass or more, cohesion or shape retainability are undesirably deteriorated.
• Polyisobutylene having a viscosity average molecular weight of from 5,000 to 200,000 can include, for example, Vistanex MML-8, MML-100, MML-120 and MML-140 (manufactured by Exxon Chemical Co. Ltd.), Opanol B80, B100, B120 and B150 (manufactured by BASF Japan Co. Ltd.), and one or more of them can be blended.
• the blending amount is from 0.1 to 20% by mass, preferably, 1 to 18% by mass and, more preferably, 3.6 to 10% by mass.
• the viscosity of the adhesive used therefor is from 1500 to 30,000 poise (at 60° C.)
• the tack of the patch is from 5 to 200 g/10 mm
• the viscosity of the adhesive is, preferably, from 2,000 to 20,000 poise (at 60° C.)
• the tack of the patch is from 20 to 150 g/10 mm. It is possible to suppress the tack for a long time on skins, pains upon peeling, skin eruptions and damages to keratin layers by using the patch showing such physical properties. If they are out of the range of the physical property values described above, they are not preferred in view of the tack to the bent portion, pains upon peeling, damages to keratin layers, skin eruptions and sliminess.
• the adhesive according to this invention is an adhesive component comprising a styrene-isoprene-styrene block copolymer, polyisobutylene, a tackifier and a plasticizer and, after controlling the blending amount of the styrene-isoprene-styrene block copolymer, polyisobutylene and the tackifier, it can be controlled so as to provide the viscosity described above by a plasticizer.
• the tack of the patch according to this invention is the tack of the patch which can be controlled mainly by controlling the composition of the adhesive.
• the feature of the patch of this invention is to control the blending amount of the adhesive ingredient to the viscosity and the tack described above.
• the tackifier preferably has the softening point of 60° C. to 150° C. and, for example, rosin ester, hydrogenated rosin ester, maleic acid modified rosin ester, polyterpen resin and petroleum resin can be used therefor and they can include, for example, Ester gum A, AA-G, H or HP (manufactured by Arakawa Chemical Co. Ltd.), Hariester L, S or P (manufactured by Harima Chemical Inc.), Pinecrystal KE-100 or KE-311 (manufactured by Arakawa Chemical Co. Ltd.), Hercolin D (manufactured by Rika Hercules Co.
• the blending amount is from 5 to 50% by mass, preferably, 7 to 45% by mass and, more preferably, 10 to 40% by mass. They are formulated such that the viscosity and each the tack are within the range as described above. With this blending ratio, tack, adhesion to skin, pains upon peeling and skin eruptions of skins can be improved greatly. If the blending amount is less than 5% by mass, it is not preferred since the tack and the deposition to the skin are lowered. Further, if it is 50% by mass or more, it is not preferred since this lowers the shape retainability, and increases pains upon peeling, damages to keratin layers, skin eruptions and sliminess.
• the plasticizer having a solution viscosity of from 10 to 100 centistoke (at 40° C.) is preferred and it can include, for example, almond oil, olive oil, camellia oil, persic oil, peanut oil, olefinic acid and liquid paraffin, and one or more of them can be blended.
• the blending ratio is from 10 to 70% by mass, preferably, 15 to 60% by mass, more preferably, 20 to 55% by mass and they are formulated such that the viscosity and the tack are each within the range described above. With this blending ratio, tack, adhesion to skins, dispersibility of chemicals in the base agent, pains upon peeling, damages to keratin layers, skin eruptions, and heat stability are greatly improved.
• the blending amount thereof is less than 10% by mass, it is not preferred since the tack, adhesion to the skins and despersibility of chemical are lowered and the viscosity of the patch is increased to undesirably make the patch not uniform and lower the operationability. Further, when it is 70% by mass or more, it is not preferred since this lowers the percutanenous absorption of chemicals and the shape retainability, and increases pains upon peeling, damages to keratin layers, skin eruptions and sliminess.
• One of more of pharmaceutically effective ingredients can be blended being selected, for example, from skin stimulating agents such as L-menthol, camphor, menthe oil, capsicum extract, capsicine, benzyl nicotinate, salicylate, glycol salicylate, analgesic and anti-inflammatory agents such as ibuprofen, piroxicam, ketoprofen, indomethacin, suprofen, loxoprofen, dichlofenac sodium, flurbiprofen, felbinac, ketrolac, narcotic analgesic agent such as fentanyl citrate and morphine hydrochloride, non-narcotic analgesic agent such as pentazoeptazocine hyrochloride, butorphanol tartarate, buprenorphin hydrochloride and eptazocine hydrobromide, dysuria remedy such as oxybutynine hydrochloride, antifungal agent such as clotrimazole, bifon
• adrenocortical hormons such as hydrocortisone butyrate, dexamethasone, dexamethasone butyrate, betamethasone, betamethasone valerate, deprodone propionate, prednisolone, fluocinonide and fluocinolone acetonide, local anesthetics such as ethyl aminobenzoate, tetracaine hydrochloride, procaine hydrochloride, lidocain hydrochloride, ⁇ -blocking agents such as propranolol hydrochloride, pindolol cateolol hdyrochloride, thymolol maleate, coronary dilator such as nitroglyceline, isosorbide, niphedine, sylthiosem hydrochloride, dipyridamole, antihistamic agents such as diphenhydramine hydrochloride, chlorophenylamine maleate and cresol hydro
• the blending ratio is from 0.001 to 30% by mass, preferably, 0.01 to 16% by mass and they also includes pharmaceutically acceptable forms of inorganic or organic salts and sufficient pharmaceutical effect can be expected by the blending ratio.
• the blending ratio is less than 0.001% by mass, no sufficient pharmaceutical effect can be provided and, when it is 30% by mass or more, it is not preferred since this causes skin eruptions with pharmaceutically effective ingredients, degrades the shape retainability of the adhesive layer and increases sliminess.
• the support in this invention is not particularly restricted and the material is selected from films, woven fabrics or non-woven fabrics, for example, of polyethylene, polypropylene, polybutadiene, polyester, nylon and polyurethane.
• polyester non-woven fabrics are used preferably since they have favorable feelings upon touch and use.
• the basis weight (weight per unit area) of the supports is preferably from 70 to 130 g/cm 2 and the thickness thereof is preferably from 0.3 to 3 mm. If the basis weight or the thickness of the support is less than the lower limit described above, the patch (laminate) tends to be creased or entangled upon appending operation failing to obtain good feeling upon use. On the other hand, if it exceeds the upper limit, the patch (laminate) lacks in softness and flexibility tending to cause a sense of incongruity such as cramp upon appending.
• the load on 50% elongation of the stretchable support used in this invention is preferably from 0.98 to 14.71 N/5 cm both in the directions of the longer side and the shorter side and, more preferably, from 1.96 to 9.81 N/5 cm in the direction of the longer side and from 0.98 to 9.81 N/5 cm in the direction of the shorter side.
• the load on 50% elongation of the support is less than the lower limit, the laminate loses so-called stiffness, so that the patch can no more be supported firmly tending to cause a difficulty in obtaining favorable feeling upon use in the appending operation.
• the load upon 50% elongation of the support exceeds the upper limit, conformity with skins becomes insufficient and it tends to be peeled easily even by slight movement in a case of appending to joints or faces.
• recovery rate upon 50% elongation of the stretchable support used in this invention is preferably from 20 to 95% and, more preferably, from 50 to 95% in the direction of the longer side and from 60 to 90% in the direction of the shorter side.
• the recovery rate upon 50% elongation of the laminate is less than the lower limit, conformity with skins becomes insufficient and it tends to be peeled even for a slight movement in a case of appending to joints or faces.
• conformity with skins is improved as the recovery rate upon 50% elongation of the laminate increases but, when it exceeds the upper limit, the patch (laminate) tends to be creased or entangled upon appending operation tending to cause a difficulty in obtaining favorable feeling in use.
• known other additives can further be blended.
• fillers such as zinc oxide, aluminum oxide, titanium dioxide, calcium carbonate, synthesis aluminum silicate, silicas and magnesium oxide, anti-oxidizing agents such as ascorbic acid, tocopherol acetate, natural vitamin E, dibutylhydroxytoluene, propyl gallate, UV-ray absorbents such as 2-hydroxy-4-methoxy benzophenone, glycol salicylate and 2-(2-hydroxy-5-methylphenyl) benzotriazole, perfuming agents or solubilizing agents such as oleic acid, glycol salicylate, benzyl alcohol, isopropyl myristate, crotamitone, oleyl alcohol, mentha oil, blue gum oil, limonen, isopregole or like other essential oils, or surface active agents known so far.
• fillers such as zinc oxide, aluminum oxide, titanium dioxide, calcium carbonate, synthesis aluminum silicate, silicas and magnesium oxide
• anti-oxidizing agents such as ascorbic
• a tackifier and a plasticizer are added to a styrene-isoprene-styrene block copolymer and polyisobutylene to adjust the viscosity and the tack, a filler and an anti-oxidant agent are optionally added at a predetermined ratio to make a mixture, which is stirred under heating in a nitrogen gas atmosphere to form a solubilized product.
• the temperature for stirring is of from 110 to 200° C. and stirring time is between 30 to 120 min.
• a pharmaceutically effective ingredient is added within a range of temperature upon stirring from 110 to 200° C.
• the solubilized product is directly cast on a support by a usual method and then covered with a releasable cover, or it may be cast once on a releasable cover and then transferred under pressure covering the support.
• the releasable cover can be selected properly from release paper, cellophane or film of polyethylene, polypropylene, polyester applied with releasing treatment.
• the patch according to this invention having the following excellent features can be provided when based only on the ingredients, as well as the tackifier, plasticizer and pharmaceutically effective ingredient as the main agent.
• Adhesion (tack) and cohesion are excellent.
• Patch was obtained based on the formulation in accordance with the preparation method described above and by cutting into a desired size.
• Stretchable woven fabrics made of a polyester material was used as a support.
• Styrene-isoprene-styrene block copolymer 16.0% (KRATON D-KX401CS) Polyisobutylene 10.0% (Vistanex LM-MS) Polyisobutylene 14.0% (Vistanex MML-140) Hydrogenated rosin ester 18.0% (Foral 105)% Liquid paraffin 37.0% (Cristol J-352) Ketoprofen 4.0% L-menthol 1.0%
• Patch was obtained based on the formulation in accordance with the preparation method described above and by cutting into a desired size.
• Stretchable woven fabrics made of a polyester material was used as a support.
• Styrene-isoprene-styrene block copolymer 25.0% (KRATON D-1107CU) Polyisobutylene 3.0% (Tetrax 5T) Polyisobutylene 1.0% (Vistanex MML-140) Hydrogenated rosin ester 10.0% (Foral 85) Liquid paraffin 50.0% (Cristol J-352) Indomethacine 5.0% Crotamiton 6.0%
• Patch was obtained based on the formulation in accordance with the preparation method described above and by cutting into a desired size. Woven fabrics made of a polyester material was used as a support.
• Styrene-isoprene-styrene block copolymer 15.0% (KRATON D-1107CU) Polyisobutylene 13.0% (Vistanex LM-MH) Polyisobutylene 13.0% (Vistanex MML-100) Maleic acid-modified rosin ester 13.0% (Malkeed) Liquid paraffin 35.0% (Cristol J-352) Glycol salicylate 5.0% L-menthol 6.0%
• Patch was obtained based on the formulation in accordance with the preparation method described above and by cutting into a desired size. Woven fabrics made of a polyester material was used as a support.
• Styrene-isopren-styrene block copolymer 29.0% (SIS-5000) Polyisobutylene 16.0% (Opanol B15SF) Polyisobutylene 1.0% (Opanol B120) Petroleum resin 18.0% (Arkon P-85) Liquid paraffin 23.0% (Cristol J-352) Titanium dioxide 3.0% Methyl salicylate 5.0% L-menthol 5.0%
• Patch was obtained based on the formulation in accordance with the preparation method described above and by cutting into a desired size. Woven fabrics made of a polyester material was used as a support.
• Styrene-isoprene-styrene block copolymer 15.0% (SIS-5000) Polyisobutylene 5.0% (Opanol B15SF) Polyisobutylene 15.0% (Opanol B120) Petroleum resin 18.0% (Edcolets 5300) Liquid paraffin 33.0% (Cristol J-352) Zinc oxide 3.0% Methyl salicylate 8.0% L-menthol 3.0%
• Patch was obtained based on the formulation in accordance with the preparation method described above and by cutting into a desired size. Woven fabrics made of a polyester material was used as a support.
• Patch was obtained based on the formulation in accordance with the preparation method described above and by cutting into a desired size. Woven fabrics made of a polyester material was used as a support.
• Patch was obtained based on the formulation in accordance with the preparation method described above and by cutting into a desired size. Woven fabrics made of a polyester material was used as a support.
• Styrene-isoprene-styrene block copolymer 17.0% (Quintack 3570C) Polyisobutylene 2.0% (Vistanex LM-MS) Polyisobutylene 1.0% (Opanol B150) Hydrogenated rosin ester 28.0% (Stebelite ester 7) Liquid paraffin 41.0% (Cristol J-352) Glycol salicylate 5.0% L-menthol 6.0%
• Patch was obtained based on the formulation in accordance with the preparation method described above and by cutting into a desired size.
• a film made of a vinyl chloride material was used as a support.
• Styrene-isoprene-styrene block copolymer 15.0% (KRATON D-1107CU) Polyisobutylene 10.0% (Tetrax 4T) Polyisobutylene 17.0% (Vistanex MML-120) Petroleum resin 20.0% (Arkon P-100) Liquid paraffin 24.0% (Cristol J-352) Methyl salicylate 8.0% L-menthol 6.0%
• Patch was obtained based on the formulation in accordance with the preparation method described above and by cutting into a desired size.
• a film made of a vinyl chloride material was used as a support.
• Patch was obtained based on the formulation in accordance with the preparation method described above and by cutting into a desired size.
• a film made of a vinyl chloride material was used as a support.
• Patch was obtained based on the formulation in accordance with the preparation method described above and by cutting into a desired size.
• a film made of a vinyl chloride material was used as a support.
• Styrene-isoprene-styrene block copolymer 18.0% (KRATON D-1107CU) Polyisobutylene 15.0% (Vistanex LM-MH) Hydrogenated rosin ester 14.0% (KE-311) Liquid paraffin 48.0% (Cristol J-352) Ketoprofen 2.0% L-menthol 3.0%
• Patch was obtained based on the formulation in accordance with the preparation method described above and by cutting into a desired size.
• a woven fabric made of a polyester material was used as a support.
• Styrene-isoprene-styrene block copolymer 18.0% (D-KX401CS) Polyisobutylene 10.0% (Vistanex MML-100) Hydrogenated rosin ester 14.0% (KE-311) Liquid paraffin 49.0% (Cristol J-352) Indomethacin 4.0% Crotamiton 5.0%
• Patch was obtained based on the formulation in accordance with the preparation method described above and by cutting into a desired size.
• a woven fabric made of a polyester material was used as a support.
• Patch was obtained based on the formulation in accordance with the preparation method described above and by cutting into a desired size.
• a woven fabric made of a polyester material was used as a support.
• Styrene-isoprene-styrene block copolymer 28.0% KRATON D-1107CU
• Hydrogenated rosin ester 42.0% KE-311) Liquid paraffin 20.0% (Crystol J-352) Glycol salicylate 5.0% L-menthol 5.0%
• Patch was obtained based on the formulation in accordance with the preparation method described above and by cutting into a desired size.
• a woven fabric made of a polyester material was used as a support.
• Styrene-isoprene-styrene block copolymer 17.0% (SIS-5000) Hydrogenated Rosin ester 52.0% (Ester gum H) Liquid paraffin 21.0% (Cristol J-352) Glycol salicylate 5.0% L-menthol 5.0%
• Patch was obtained based on the formulation in accordance with the preparation method described above and by cutting into a desired size.
• a film fabric made of a vinyl chloride material was used as a support.
• a patch preliminarily left in a thermostable chamber at 25° C. for 30 min or more was prepared to a face of 20 mm width and about 100 mm length. It was mated at one end to a test board made of a phenol resin of 25 mm width and 50 mm length and left at 25° C. in a thermostable chamber for 30 min or more and appended rapidly by a width of 20 mm and a length of 50 mm in the same manner, a rubber roller of a weight of 800 g was passed twice over the product at a speed of 300 mm per one minute.
• the viscosity of plasters was measured by a Shimazu flow tester manufactured by Shimazu Seisakusho Co. Ltd. About 2 g of plaster was filled in a cylinder having an area of 100 mm 2 and a height of 40 mm and previously kept at 60° C., and left for 5 min. A die having a fine tube of a diameter of 0.5 mm and a length of 1 mm was previously attached on the lower portion of the cylinder. After leaving it for 5 min, the surface of 100 mm 2 at the upper portion of the cylinder was pressed by a piston under a load of 10 kg.
• the viscosity of the adhesive used for the patch and the tack in the patch according to this invention agent are defined each within the specified range, pains upon peeling are less, damages to the keratin layers are moderated remarkably, safety to skins is high, heat stability is excellent and, further, the tack is favorable, so that it can be utilized as various kinds of application uses of the medical patch, which are extremely useful industrially.

Landscapes

• Health & Medical Sciences (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Engineering & Computer Science (AREA)
• Life Sciences & Earth Sciences (AREA)
• Chemical & Material Sciences (AREA)
• General Health & Medical Sciences (AREA)
• Public Health (AREA)
• Medicinal Chemistry (AREA)
• Dermatology (AREA)
• Pharmacology & Pharmacy (AREA)
• Veterinary Medicine (AREA)
• Animal Behavior & Ethology (AREA)
• Epidemiology (AREA)
• Inorganic Chemistry (AREA)
• Botany (AREA)
• Chemical Kinetics & Catalysis (AREA)
• General Chemical & Material Sciences (AREA)
• Rheumatology (AREA)
• Pain & Pain Management (AREA)
• Organic Chemistry (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Medicinal Preparation (AREA)
• Materials For Medical Uses (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Priority Applications (1)

Applications Claiming Priority (2)

Related Child Applications (1)

Publications (1)

Family

ID=18449244

Family Applications (2)

Family Applications After (1)

Country Status (13)

Cited By (24)

Families Citing this family (32)

Citations (5)

Family Cites Families (4)

• 2000
  • 2000-12-15 AT AT00981746T patent/ATE353636T1/de not_active IP Right Cessation
  • 2000-12-15 KR KR1020027005288A patent/KR100730228B1/ko active IP Right Grant
  • 2000-12-15 BR BRPI0016368A patent/BRPI0016368B8/pt not_active IP Right Cessation
  • 2000-12-15 WO PCT/JP2000/008893 patent/WO2001043729A1/ja active IP Right Grant
  • 2000-12-15 US US10/149,942 patent/US20030109819A1/en not_active Abandoned
  • 2000-12-15 DE DE60033426T patent/DE60033426T2/de not_active Expired - Lifetime
  • 2000-12-15 EP EP00981746A patent/EP1238664B1/en not_active Expired - Lifetime
  • 2000-12-15 ES ES00981746T patent/ES2281366T3/es not_active Expired - Lifetime
  • 2000-12-15 AU AU18911/01A patent/AU780058B2/en not_active Expired
  • 2000-12-15 JP JP2001544668A patent/JP4705301B2/ja not_active Expired - Lifetime
  • 2000-12-15 PT PT00981746T patent/PT1238664E/pt unknown
  • 2000-12-15 CN CNB008170363A patent/CN1235572C/zh not_active Expired - Lifetime
  • 2000-12-15 CA CA002394506A patent/CA2394506C/en not_active Expired - Lifetime
• 2006
  • 2006-12-05 US US11/634,481 patent/US7250546B2/en not_active Expired - Lifetime

Patent Citations (5)

Also Published As

Similar Documents

Legal Events